Preferred Label : cemiplimab;
UNII : 6QVL057INT;
Origin ID : C000627974;
UMLS CUI : C4724806;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3488409/fr/libtayo-cemiplimab-cancer-bronchopulmonaire-non-a-petites-cellules-cbnpc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
cemiplimab
antibodies, monoclonal, humanized
antineoplastic combined chemotherapy protocols
adult
platinum compounds
PD-L1 Positive
evaluation of the transparency committee
carcinoma, non-small-cell lung
cemiplimab
---
https://www.has-sante.fr/jcms/p_3461359/fr/libtayo-cemiplimab-carcinome-epidermoide-cutane-metastatique-ou-localement-avance-cecm-ou-cecla
2023
false
false
false
France
skin neoplasms
treatment outcome
insurance, health, reimbursement
Metastatic Skin Squamous Cell Carcinoma
Locally Advanced Skin Squamous Cell Carcinoma
infusions, intravenous
Antineoplastic Agents, Immunological
cemiplimab
antibodies, monoclonal, humanized
evaluation of the transparency committee
cemiplimab
carcinoma, squamous cell
---
https://www.has-sante.fr/jcms/p_3430191/fr/libtayo-cemiplimab-cancer-du-col-de-l-uterus
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
cemiplimab
infusions, intravenous
Antineoplastic Agents, Immunological
Metastatic Cervical Carcinoma
Recurrent Cervical Carcinoma
Refractory Cervical Carcinoma
evaluation of the transparency committee
cemiplimab
uterine cervical neoplasms
---
https://www.has-sante.fr/jcms/p_3308691/fr/libtayo-350mg-cemiplimab
2022
false
false
false
France
antibodies, monoclonal, humanized
insurance, health, reimbursement
Locally Advanced Skin Squamous Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma
carcinoma, squamous cell
skin neoplasms
cemiplimab
infusions, intravenous
Antineoplastic Agents, Immunological
treatment outcome
evaluation of the transparency committee
cemiplimab
---
https://www.has-sante.fr/jcms/p_3367549/fr/libtayo-cemiplimab-cbcla-ou-cbcm
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
cemiplimab
infusions, intravenous
Antineoplastic Agents, Immunological
cemiplimab
Locally Advanced Basal Cell Carcinoma
carcinoma, basal cell
Tumor Progression
Metastatic Basal Cell Carcinoma
evaluation of the transparency committee
---
https://ansm.sante.fr/tableau-marr/cemiplimab
2022
false
false
false
France
French
risk management
patients guideline
cemiplimab
Antineoplastic Agents, Immunological
infusions, intravenous
cemiplimab
drug monitoring
---
https://www.has-sante.fr/jcms/p_3299037/fr/libtayo-350-mg-cemiplimab-cbnpc
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
cemiplimab
cemiplimab
Antineoplastic Agents, Immunological
adult
carcinoma, non-small-cell lung
PD-L1 Positive
PD-L1 Overexpression
neoplasm metastasis
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3166985/fr/libtayo
2020
false
false
false
France
infusions, intravenous
treatment outcome
cemiplimab
cemiplimab
Antineoplastic Agents, Immunological
insurance, health, reimbursement
neoplasm metastasis
Metastatic Skin Squamous Cell Carcinoma
Locally Advanced Skin Squamous Cell Carcinoma
adult
skin neoplasms
carcinoma, squamous cell
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/libtayo-cancer-cutane-5090.html
2020
false
false
false
Canada
French
drug evaluation
cemiplimab
Locally Advanced Skin Squamous Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma
carcinoma, squamous cell
skin neoplasms
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
cemiplimab
cemiplimab
adult
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
Locally Advanced Skin Squamous Cell Carcinoma
carcinoma, squamous cell
skin neoplasms
infusions, intravenous
programmed cell death 1 receptor
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
survival analysis
drug evaluation, preclinical
Metastatic Skin Squamous Cell Carcinoma
cemiplimab
antibodies, monoclonal
antibodies, monoclonal
---
